1. Home
  2. FATE vs VYGR Comparison

FATE vs VYGR Comparison

Compare FATE & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • VYGR
  • Stock Information
  • Founded
  • FATE 2007
  • VYGR 2013
  • Country
  • FATE United States
  • VYGR United States
  • Employees
  • FATE N/A
  • VYGR N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • VYGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • FATE Health Care
  • VYGR Health Care
  • Exchange
  • FATE Nasdaq
  • VYGR Nasdaq
  • Market Cap
  • FATE 142.4M
  • VYGR 297.7M
  • IPO Year
  • FATE 2013
  • VYGR 2015
  • Fundamental
  • Price
  • FATE $1.20
  • VYGR $4.21
  • Analyst Decision
  • FATE Hold
  • VYGR Strong Buy
  • Analyst Count
  • FATE 10
  • VYGR 9
  • Target Price
  • FATE $6.75
  • VYGR $15.53
  • AVG Volume (30 Days)
  • FATE 1.7M
  • VYGR 325.0K
  • Earning Date
  • FATE 02-24-2025
  • VYGR 02-26-2025
  • Dividend Yield
  • FATE N/A
  • VYGR N/A
  • EPS Growth
  • FATE N/A
  • VYGR N/A
  • EPS
  • FATE N/A
  • VYGR 0.47
  • Revenue
  • FATE $13,447,000.00
  • VYGR $163,784,000.00
  • Revenue This Year
  • FATE N/A
  • VYGR N/A
  • Revenue Next Year
  • FATE N/A
  • VYGR N/A
  • P/E Ratio
  • FATE N/A
  • VYGR $8.97
  • Revenue Growth
  • FATE N/A
  • VYGR 3.40
  • 52 Week Low
  • FATE $1.04
  • VYGR $4.13
  • 52 Week High
  • FATE $8.83
  • VYGR $10.66
  • Technical
  • Relative Strength Index (RSI)
  • FATE 37.03
  • VYGR 25.61
  • Support Level
  • FATE $1.21
  • VYGR $5.16
  • Resistance Level
  • FATE $1.49
  • VYGR $5.78
  • Average True Range (ATR)
  • FATE 0.09
  • VYGR 0.33
  • MACD
  • FATE 0.02
  • VYGR -0.06
  • Stochastic Oscillator
  • FATE 10.34
  • VYGR 4.36

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: